Cellerys will start a multi-center phase IIa trial in 2022 as the next important milestone to bring RED4MS to patients.RED4MS is a unique approach to treat and prevent multiple sclerosis (“MS”). It has been developed over the past decade and has successfully passed phase Ib clinical testing.


Wagistrasse 21, 8952 Schlieren, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business